Sammanfattning
Given today’s pharmaceutical markets, it is difficult to develop new drugs for diseases that primarily affect people in developing countries. Supplementary business models are needed to address this. Experience with developing drugs for rare diseases gives some insight into promising incentive structures, but we also need new mechanisms such as prizes, open source, research funds and product development partnerships. Norway should support mechanisms of this kind, both at home and abroad.